Enanta Pharmaceuticals will present preclinical data for its KIT inhibitor EDP‑978 at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, scheduled for February 27–March 2, 2026. The presentation will include two poster sessions on Friday, February 27 at 2:45 PM EST in Hall E of the convention center.
The poster sessions, titled “Discovery of a Potent and Selective KIT Inhibitor for Treatment of Mast Cell‑Mediated Diseases” and “EDP‑978, a Potent KIT Inhibitor, Demonstrated Dose‑Dependent Target‑Engagement and a Favorable Pharmacokinetic Profile with Once‑Daily Dosing Potential in Humans,” will provide the first public disclosure of the candidate’s preclinical safety and pharmacology profile.
Enanta’s immunology pipeline, which also includes selective STAT6 and MRGPRX2 inhibitors, is positioned to offer oral small‑molecule alternatives to biologics for type‑2 immune diseases such as chronic spontaneous urticaria. The preclinical data support the company’s plan to file an IND for EDP‑978 in the first quarter of 2026, a critical step toward clinical development.
CEO Jay R. Luly emphasized the company’s commitment to advancing its immunology portfolio, noting that the new KIT inhibitor “represents a significant advance in our strategy to develop oral therapies for mast cell‑mediated conditions.” The presentation is expected to generate interest among researchers and investors looking for novel treatments in the growing CSU market.
The AAAAI conference will bring together leading clinicians and scientists in allergy, asthma, and immunology, providing Enanta with a platform to showcase the drug’s potency, selectivity, and once‑daily dosing potential, which could differentiate it from existing biologic therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.